Tretinoin

Generic Name: Tretinoin

Brand Names: Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈O_₂

CAS Number: 302-79-4

Unique Ingredient Identifier: 5688UTC01R

Background: Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...

Indication: Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...

Associated Conditions: Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin

Associated Therapies: -

Clinical Trials

Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris

Phase 2

Completed

Conditions: Facial Acne Vulgaris

Interventions: Drug: retinyl palmitate
Drug: Tretinoin

First Posted Date: 2019-09-06

Last Posted Date: 2022-11-14

Lead Sponsor: Assiut University

Target Recruit Count: 20

Registration Number: NCT04080869

Locations: 🇪🇬
Assiut University Hospital, Assiut, Egypt

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Phase 2

Completed

Conditions: Adenoid Cystic Carcinoma

Interventions: Drug: Tretinoin

First Posted Date: 2019-06-27

Last Posted Date: 2023-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03999684

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Phase 2

Completed

Conditions: Prostatic Neoplasms
Prostate Cancer
Prostate Neoplasms

Interventions: Drug: 5-Azacitidine
Drug: all trans retinoic acid
Drug: Lupron

First Posted Date: 2018-06-28

Last Posted Date: 2024-04-30

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 14

Registration Number: NCT03572387

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis

Early Phase 1

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)

Interventions: Drug: Retinoic acid
Device: Laser
Device: Sham treatment

First Posted Date: 2018-04-09

Last Posted Date: 2024-06-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 20

Registration Number: NCT03491267

Locations: 🇺🇸
Johns Hopkins School of Medicine, Dermatology Department, Baltimore, Maryland, United States

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

Early Phase 1

Completed

Conditions: Melasma

Interventions: Device: colorimetry measurement
Drug: Retinoic acid
Drug: sunscreen
Drug: Niacinamide

First Posted Date: 2018-01-08

Last Posted Date: 2018-01-09

Lead Sponsor: Universidad Autonoma de San Luis Potosí

Target Recruit Count: 28

Registration Number: NCT03392623

An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Phase 2

Terminated

Conditions: Cholangitis, Sclerosing

Interventions: Drug: All-trans retinoic acid

First Posted Date: 2017-12-02

Last Posted Date: 2021-08-09

Lead Sponsor: Yale University

Target Recruit Count: 2

Registration Number: NCT03359174

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Stromal TARgeting for PAncreatic Cancer (STAR_PAC)

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: ATRA
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2017-10-11

Last Posted Date: 2020-01-22

Lead Sponsor: Barts & The London NHS Trust

Target Recruit Count: 29

Registration Number: NCT03307148

Locations: 🇬🇧
Barts and The London NHS, St Bartholomew's Hospital, London, United Kingdom
🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇬🇧
Imperial College NHS Trust, London, United Kingdom

and more 1 locations

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2

Conditions: Immune Thrombocytopenia

Interventions: Drug: Rituximab
Drug: All-trans retinoic acid

First Posted Date: 2017-10-09

Last Posted Date: 2021-01-20

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 168

Registration Number: NCT03304288

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳
Navy General Hospital, Beijing, Beijing, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China

and more 1 locations

Nivolumab With Chemotherapy in Refractory MDS

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Nivolumab
Drug: Fludarabine
Drug: Cytarabine
Drug: Melphalan
Drug: Azacitidine
Drug: all trans retinoic acid
Drug: Cyclophosphamide
Drug: Sildenafil

First Posted Date: 2017-08-23

Last Posted Date: 2019-04-05

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 2

Registration Number: NCT03259516

Locations: 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy